Brief: Neurizon Therapeutics Says US FDA Denies Fast Track Designation For NUZ-001
02/01/2026 01:29
Jan 2 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX: REGULATORY AND DEVELOPMENT UPDATE UPDATES ON NUZ-001 DEVELOPMENT FOR ALS US FDA DENIES FAST TRACK DESIGNATION FOR NUZ-001 RECEIVED REGULATORY CORRESPONDENCE FROM US FDA STATING REQUEST FOR FAST TRACK DESIGNATION DENIED AT THIS TIME Further company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO